Indian pharmaceutical exporters have urged the government to reconsider its recent decision prohibiting the export of drugs that are meant exclusively for the domestic market.
Exporters argue that the move could negatively impact India’s position as a global supplier of affordable medicines, particularly to developing countries that rely on Indian formulations. Industry representatives said the rule could disrupt supply chains and dent export revenues at a time when the sector is already grappling with rising input costs and regulatory hurdles abroad.
They further pointed out that several formulations categorized as “India-only” are in demand in overseas markets, especially in Africa, South Asia, and parts of Latin America. Restricting exports, they say, would not only limit business opportunities for Indian manufacturers but also create shortages in dependent markets.
Export bodies have approached the commerce and health ministries, seeking a rollback or at least a relaxation of the ban to allow case-by-case approvals. The government, however, has defended the rule as a measure to ensure uninterrupted availability of essential medicines for domestic patients.
Discussions between the industry and policymakers are expected in the coming weeks, with exporters hoping for a balanced solution that safeguards both domestic healthcare needs and India’s global pharmaceutical footprint.
